Categories
Health

Intravenous Iron Drugs Market to Top USD 3,000 Million by 2026

According to the report, The global intravenous iron drugs market in 2019 was approximately USD 1,800 Million. The market is expected to grow above a CAGR of 8.0% and is anticipated to reach over USD 3,000 Million by 2026.

Intravenous iron drugs and oral iron supplementation are considered as primary therapies for iron deficiency. Moreover, efficacy of intravenous iron drugs and oral iron supplementation has played a key role in the adoption of iron supplement drugs. IV iron drugs are often preferred over oral iron supplementation because of high gastrointestinal AE rate of oral iron supplements. A long treatment of oral iron supplements is needed to cure anemia. IV iron drugs are directly absorbed in the blood which results in the faster increase of Hb level in the body. IV iron drugs is safe and is increasingly adopted by physicians and other medical professionals.

Get Sample Research Report HERE

The intravenous iron drugs market research report delivers an acute valuation and taxonomy of the intravenous iron drugs industry by practically splitting the market on the basis of different types, applications, and regions. Through the analysis of the historical and projected trends, all the segments and sub-segments were evaluated through the bottom-up approach, and different market sizes have been projected for FY 2020 to FY 2026. The regional segmentation of the intravenous iron drugs industry includes the complete classification of all the major continents including North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. Further, country-wise data for the intravenous iron drugs industry is provided for the leading economies of the world.

The intravenous iron drugs market is segmented based on product, application, and region. On the basis of product, the market is classified into iron dextran, iron sucrose, ferric carboxymaltose, and others. On the basis of application, the market is classified into chronic kidney disease, inflammatory bowel disease, cancer, and others.

Browse detail report with in-depth TOC HERE

Some of the essential players operating in the intravenous iron drugs market, but not restricted to include Allergan Inc., Daiichi Sankyo Company Ltd., Rockwell Medical Technologies Inc., AMAG Pharmaceuticals Inc., Sanofi, Fresenius Medical Care AG & Co., Vifor Pharma Management Ltd., Pharmacosmos A/S, Shield Therapeutics Plc, American Regent Inc., and others.

Contact Us:

Facts & Factors

USA: 1 (347) 690-0211

Email: [email protected]

Web: https://www.fnfresearch.com